These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 16082437)

  • 1. Moving beyond the cost per quality-adjusted life year: modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents.
    Shrive FM; Ghali WA; Lewis S; Donaldson C; Knudtson ML; Manns BJ
    Can J Cardiol; 2005 Jul; 21(9):783-7. PubMed ID: 16082437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of sirolimus-eluting stents.
    Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
    CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
    Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
    Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of Sirolimus Eluting stents in interventional cardiology.
    Di Mario C; Griffiths H; O'Rourke B; Kaddoura S
    Int J Cardiol; 2004 Jun; 95(2-3):117-21. PubMed ID: 15193808
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
    Morice MC; Serruys PW; Barragan P; Bode C; Van Es GA; Stoll HP; Snead D; Mauri L; Cutlip DE; Sousa E
    J Am Coll Cardiol; 2007 Oct; 50(14):1299-304. PubMed ID: 17903626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease.
    Minutello RM; Bhagan S; Sharma A; Slotwiner AJ; Feldman DN; Cuomo LJ; Wong SC
    J Interv Cardiol; 2007 Dec; 20(6):458-65. PubMed ID: 18042050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus-eluting stents. (The results of the five-year use for the treatment of coronary artery disease).
    Krylov AL
    Angiol Sosud Khir; 2006; 12(4):71-82. PubMed ID: 17679960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dollars and sense of drug-eluting stents.
    Brophy JM
    CMAJ; 2005 Feb; 172(3):361-2. PubMed ID: 15684119
    [No Abstract]   [Full Text] [Related]  

  • 15. The fate of patients with clinical recurrence after sirolimus-eluting stent implantation (a two-year follow-up analysis from the SIRIUS trial).
    Moussa ID; Moses JW; Kuntz RE; Holmes DR; Popma JJ; Teirstein PS; Wong SC; Leon MB
    Am J Cardiol; 2006 Jun; 97(11):1582-4. PubMed ID: 16728218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.
    Ge J; Qian J; Wang X; Wang Q; Yan W; Yan Y; Fan B; Ge L; Liu X
    Catheter Cardiovasc Interv; 2007 Feb; 69(2):198-202. PubMed ID: 17195205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus-eluting coronary stents.
    Sharma S; Bhambi B; Nyitray W
    N Engl J Med; 2002 Oct; 347(16):1285; author reply 1285. PubMed ID: 12393833
    [No Abstract]   [Full Text] [Related]  

  • 20. A cost-effectiveness analysis of a hypothetical catheter-based strategy for the detection and treatment of vulnerable coronary plaques with drug-eluting stents.
    Bosch JL; Beinfeld MT; Muller JE; Brady T; Gazelle GS
    J Interv Cardiol; 2005 Oct; 18(5):339-49. PubMed ID: 16202108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.